U.S., March 4 -- ClinicalTrials.gov registry received information related to the study (NCT06854224) titled 'Orexin Antagonism for Suicide Risk: a Proof-of-Concept Clinical Trial' on Feb. 25.
Brief Summary: The goal of this proof-of-concept clinical trial is to evaluate the initial safety, feasibility, and tolerability of the orexin mixed antagonist suvorexant in a sample of veteran adults with Major Depressive Disorder and elevated suicide risk. The main question it aims to answer is: Is Suvorexant safe, feasible, and tolerable for participants?
Participants will:
* Take Surovexant every day for four weeks (10mg in the first two weeks and 20mg in the second two weeks)
* Visit the medical center at the beginning of the study (week 1), a...